Globus Medical (GMED) vs Insulet (PODD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Globus Medical (GMED) has outperformed Insulet (PODD) over the past year, gaining 24.3% versus a loss of 57.1%. Over five years, GMED leads with a -3.5% price change compared with -55.3% for PODD. Globus Medical is the larger company by market cap ($9.90 billion vs $9.32 billion), about 1.1 times the size, while Insulet is growing revenue faster (+30.7% vs +16.7%).
On valuation, Globus Medical trades at a lower forward P/E (13.7x vs 17.4x for Insulet). Globus Medical converts more of its revenue into profit, with a net margin of 18.3% versus 9.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMED | PODD |
|---|---|---|
| Share price | $73.75 | $134.36 |
| Market cap | $9.90B | $9.32B |
| 1-day change | -3.51% | -0.27% |
| YTD return | -15.53% | -52.73% |
| 1-year return | +24.35% | -57.14% |
| 5-year return | -3.51% | -55.29% |
| P/E ratio (TTM) | 18.91 | 25.16 |
| Forward P/E | 13.66 | 17.38 |
| EPS (TTM) | $3.90 | $5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.94B | $2.71B |
| Revenue growth (YoY) | +16.65% | +30.73% |
| Net income (latest FY) | $537.87M | $247.10M |
| Gross margin | 67.41% | 71.63% |
| Operating margin | 16.33% | 17.50% |
| Net margin | 18.30% | 9.12% |
| 52-week high | $101.40 | $354.88 |
| 52-week low | $56.50 | $126.40 |
| Distance from 52-week high | -27.27% | -62.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +36.84% | +27.24% |
| Average volume | 1.50M | 1.69M |
| Shares outstanding | 111.83M | 69.35M |
| Employees | 6,000 | 5,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GMED has outperformed PODD by 81.5 percentage points over the past year.
- Insulet trades at a higher earnings multiple (25.2x vs 18.9x trailing P/E).
- Globus Medical is more profitable, keeping 18.3 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +16.65%).
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
GMED vs PODD FAQ
Which is bigger, Globus Medical or Insulet?
Globus Medical (GMED) is larger, with a market capitalization of $9.90B compared with $9.32B for Insulet (PODD).
Which stock has performed better over the past year, GMED or PODD?
GMED returned +24.35% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMED or PODD?
GMED has the lower trailing P/E at 18.9, versus 25.2 for PODD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Globus Medical and Insulet in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.